Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003299 · ClinicalTrials.gov registry record · Phase 3
Cisplatin Plus Etoposide With or Without Paclitaxel in Treating Patients With Extensive-Stage Small Cell Lung Cancer
A Phase 3 study, sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- Phase 3
- Development phase
- 587
- Enrollment target
NCT00003299 is a Phase 3 study that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 587 participants.
The verdict
NCT00003299, a Phase 3 study, has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 587 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known whether cisplatin, etoposide, and paclitaxel are more effective than cisplatin and etoposide alone in treating patients with extensive-stage small cell lung cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of cisplatin plus etoposide with or without paclitaxel in treating patients with extensive-stage small cell lung cancer.
Interventions
- DRUG cisplatin
- DRUG paclitaxel
- DRUG etoposide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 587 participants |
| Start Date | 1998-04 |
| Est. Completion | 2006-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003299
The ClinicalTrials.gov registry entry for NCT00003299 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 587 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which cisplatin is the first listed.
NCT00003299 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003299 about?
NCT00003299 is a clinical study titled "Cisplatin Plus Etoposide With or Without Paclitaxel in Treating Patients With Extensive-Stage Small Cell Lung Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known whether cisplatin, etoposide, and paclitaxel are more effective than cisplatin and etoposide alone in tr...
What is the current status of trial NCT00003299?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 587 participants. The study started on 1998-04. Estimated completion is 2006-01.
What interventions are being tested in trial NCT00003299?
The interventions under investigation include: cisplatin (DRUG), paclitaxel (DRUG), etoposide (DRUG).
Who is sponsoring clinical trial NCT00003299?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.